Portal de Periódicos da CAPES

Activity of Imipenem-Relebactam against a Large Collection of Pseudomonas aeruginosa Clinical Isolates and Isogenic β-Lactam-Resistant Mutants

2019; American Society for Microbiology; Volume: 64; Issue: 2 Linguagem: Inglês

10.1128/aac.02165-19

1098-6596

Pablo A. Fraile-Ribot, Laura Zamorano, Rocío Orellana, Ester del Barrio-Tofiño, Irina Sánchez-Diener, Sara Cortés-Lara, Carla López-Causapé, Gabriel Cabot, Germán Bou, Luis Martínez‐Martínez, Antonio Oliver, Fátima Galán‐Sánchez, Irene Gracia, Manuel Antonio Agüero Rodríguez, L. Hibberd Martin, Juan Manuel Sánchez, Laura Viñuela, Ma Victoria García, José Antonio Lepe, Javier Aznar, Inma López-Hernández, Cristina Seral, Francisco Javier Castillo, Ana Isabel López‐Calleja, Carmen Aspíroz, Pedro de la Iglesia, Susana Sánchez Ramón, Elena Riera, María Cruz Pérez, Carmen Gallegos, J. H. Calvo, María Dolores Quesada, Francesc Marco, Yannick Hoyos-Mallecot, Juan Pablo Horcajada, Nieves Larrosa, Juan José González‐López, Fé Tubau, Sílvia Capilla, Mar Olga Pérez-Moreno, Ma José Centelles, Emma Padilla, Alba Rivera, Beatriz Mirelis, Raquel Elisa Rodríguez-Tarazona, Noelia Arenal-Andrés, María del Pilar Ortega, Gregoria Megías, Inmaculada García, Cristina Colmenarejo, José Carlos González, Nora Mariela Martínez, Bárbara Gomila, Salvador Giner, Nuria Tormo, Eugenio Garduño, José Andrés Agulla, Alejandro Seoane, J. Pita, Isabel Paz Vidal, David Mauricio Guzmán, Marta García, María de Toro, Gema Barbeito, Fernando Artiles, José Manuel Azcona, Yolanda Sáenz, José A. Oteo, Ana Rodrı́guez, Jennifer Villa, Fernando Cháves, Emilia Cercenado, Teresa Alarcón, Nelly Daniela Zurita, Irene Merino, María Isabel Morosini, Rafael Cantón, María Isabel Sánchez, Laura Moreno, Genoveva Yagüe, José Leiva, José Luís González Barrios, Andrés Canut, Jesús Oteo,

Antibiotics Pharmacokinetics and Efficacy

Imipenem and imipenem-relebactam MICs were determined for 1,445 Pseudomonas aeruginosa clinical isolates and a large panel of isogenic mutants showing the most relevant mutation-driven β-lactam resistance mechanisms. Imipenem-relebactam showed the highest susceptibility rate (97.3%), followed by colistin and ceftolozane-tazobactam (both 94.6%).